1-4 of 4
treat trial
Close
Sort by
Journal Articles

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Patrick T. McGann, MD, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Tomoyuki Mizuno, PhD, Karen Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Charles T. Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP
Journal: Blood
Blood (2018) 132 (Supplement 1): 507.
https://doi.org/10.1182/blood-2018-99-112909
Published: 2018
Journal Articles

Personalized Hydroxyurea Dosing to Reduce Time to MTD and Optimize the HbF Response: Results from the TREAT Study

Patrick T. McGann, MD MS, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Kathryn L McElhinney, BS, Thad A. Howard, MS, Tomoyuki Mizuno, PhD, Theodosia A. Kalfa, MD PhD, Karen Kalinyak, MD, Punam Malik, MD, Charles T. Quinn, MD MS, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP
Journal: Blood
Blood (2017) 130 (Supplement 1): 615.
https://doi.org/10.1182/blood.V130.Suppl_1.615.615
Published: 2017
Journal Articles

Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study

Patrick T. McGann, MD MS, Min Dong, PhD, Anu Marahatta, PhD, Thad A. Howard, MS, Tomoyuki Mizuno, PhD, Karen A. Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Omar Niss, MD, Charles T Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3652.
https://doi.org/10.1182/blood.V128.22.3652.3652
Published: 2016
Journal Articles

Poor ESA Responders As Defined By Week 4 Hemoglobin Response Have Greater ESA Dosing but Worse Cardiovascular Outcomes in Patients with Anemia of Chronic Kidney Disease (CKD) Not on Dialysis

Robert C. Kane, MD, Qing Xu, PhD, Rajeshwari Sridhara, PhD, Justin Earp, PhD
Journal: Blood
Blood (2014) 124 (21): 4016.
https://doi.org/10.1182/blood.V124.21.4016.4016
Published: 2014